Orchard Therapeutics plc Q4 2022 Earnings Call Transcript
| ORTXDelisted Stock | USD 5.27 0.01 0.19% |
Slightly above 62% of Orchard Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Orchard Therapeutics PLC suggests that many traders are alarmed regarding Orchard Therapeutics' prospects. Orchard Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Orchard Therapeutics' earnings reports, geopolitical events, and overall market trends.
Orchard |
Orchard Therapeutics plc Q4 2022 Earnings Call Transcript March 10, 2023 Bobby Gaspar Hello, everyone. Im Bobby Gaspar, CEO and Co-Founder of Orchard. Im especially delighted to host our fourth quarter 2022 conference call, where we have a number of important corporate and regulatory updates, along with providing our full financial results. Before
Read at finance.yahoo.com
 |
Orchard Therapeutics Fundamental Analysis
We analyze Orchard Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orchard Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orchard Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Orchard Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Orchard Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Orchard Therapeutics stock to make a market-neutral strategy. Peer analysis of Orchard Therapeutics could also be used in its relative valuation, which is a method of valuing Orchard Therapeutics by comparing valuation metrics with similar companies.
Peers
Orchard Therapeutics Related Equities
| ELDN | Eledon Pharmaceuticals | 8.92 | ||||
| PDSB | PDS Biotechnology | 4.65 | ||||
| TERN | Terns Pharmaceuticals | 3.41 | ||||
| HOOK | Hookipa Pharma | 1.16 | ||||
| DAWN | Day One | 1.81 | ||||
| ABOS | Acumen Pharmaceuticals | 2.98 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.60 | ||||
| XFOR | X4 Pharmaceuticals | 5.13 | ||||
| INZY | Inozyme Pharma | 6.09 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Orchard Stock
If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |